References
- Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999;341(17):1284–1291. doi:https://doi.org/10.1056/NEJM199910213411707.
- Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380. doi:https://doi.org/10.1016/j.ajo.2004.03.022.
- Atmaca LS. Fundus changes associated with Behcet’s disease. Graefes Arch Clin Exp Ophthalmol. 1999;227(4):340–344. doi:https://doi.org/10.1007/BF02169409.
- Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656–1662. doi:https://doi.org/10.1136/ard.2007.080432.
- Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet’s disease: review and basis for recommendations. Rheumatology (Oxford). 2007;46(5):736–741. doi:https://doi.org/10.1093/rheumatology/kem034.
- Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(786–96):e3. doi:https://doi.org/10.1016/j.ophtha.2013.09.048.
- Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi:https://doi.org/10.1016/S0002-9394(00)00659-0.
- Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open label trial. Arthritis Rheum. 2005;52(8):2478–2484. doi:https://doi.org/10.1002/art.21231.
- Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362–1368.
- Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet’s disease: a multicenter study. Ophthalmology. 2014;121(10):1877–1884. doi:https://doi.org/10.1016/j.ophtha.2014.04.042.
- Tugal-Tutkun I, Herbort CP, Khairallah M, et al. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539. doi:https://doi.org/10.1007/s10792-008-9263-x.
- Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423–431. doi:https://doi.org/10.1136/bjo.87.4.423.
- Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol. 2000;84(12):1437–1438. doi:https://doi.org/10.1136/bjo.84.12.1432g.
- Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912. doi:https://doi.org/10.1001/archopht.123.7.903.
- Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial [comment]. Lancet. 2002;359(9317):1541–1549. doi:https://doi.org/10.1016/S0140-6736(02)08512-4.
- Ito T, Sonoda KH, Hijioka K, et al. Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration. Jpn J Ophthalmol. 2010;54(5):502–504. doi:https://doi.org/10.1007/s10384-010-0859-0.
- Murdaca G, Spanò F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52. doi:https://doi.org/10.1517/14740338.2016.1112375.
- Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395. doi:https://doi.org/10.1056/NEJMoa0904492.
- Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3. doi:https://doi.org/10.1053/j.gastro.2013.10.052.
- Arida A, Fragiadaki K, Giavri E, Sfikakis P. Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61–70. doi:https://doi.org/10.1016/j.semarthrit.2010.09.002.
- Zierhut M, Pavesio C, Ohno S, Orefice F, Rao NA. Intraocular inflammation. Berlin: Springer; 2016:300.
- Nicoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology. 2007;46(7):1161–1164. doi:https://doi.org/10.1093/rheumatology/kem101.
- Adan A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet’s disease after withdrawal of infusions. Int Ophthalmol. 2010;30(5):577–581. doi:https://doi.org/10.1007/s10792-010-9372-1.
- Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58(1):75–80. doi:https://doi.org/10.1007/s10384-013-0283-3.
- Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014;22(2):96–101. doi:https://doi.org/10.3109/09273948.2013.812222.
- Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21(6):468–474. doi:https://doi.org/10.3109/09273948.2013.779727.
- Mushtaq B, Sabed T, Situnayake RD, et al. Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye. 2007;21(6):824–825. doi:https://doi.org/10.1038/sj.eye.6702352.
- Van Laar JAM, Mossotten T, van Daele PLA, et al. Adalimumab: a new modality for Behcet’s disease? Ann Rheum Dis. 2007;66(4):565–566. doi:https://doi.org/10.1136/ard.2006.064279.
- Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32:58–62.
- Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease related uveitis. Rheumatol Int. 2011;31(2):243–245. doi:https://doi.org/10.1007/s00296-009-1178-y.
- Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:54–57.
- Bawazeer A, Raffa LH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;18(3):226–232. doi:https://doi.org/10.3109/09273948.2010.483314.